Yizhuang, Beijing – Oct. 10, 2013 –CasGene Biotech, leading gene-engineered rodent model provider, announced a collaboration with iPhase Parm, a leading CRO company focused on drug discovery and DMPK. The two companies will work together to provide better service to drug development industry.
Headquartered in Beijing, CasGene Biotech,Ltd focused on providing reliable, fast and affordable gene-engineered rodent models such as transgenic mouse and knockout mouse. Utilizing conventional ES method, TALEN and Optimized Cas9/CRISP technology, CasGene Biotech has established more 40 knockout mice and dozens of transgenic mice. In 2014, CasGene Biotech generated several knockout rat model.
"Our collaboration with iPhase Pharm and application of their platform of phenotype analysis and clinical diagnosis, empowered us to provide better services to our customer in academia and pharmaceutical industry" stated Dr. Phenix Wang, Vice President and CTO, CasGene Biotech.
About CasGene Biotech,Ltd.
CasGene Biotech is a Chinese contract research organization (CRO) specializing in providing gene-engineered rodent models founded by returned scientists trained in renowned universities of United States and local experts in animal models.Headquartered in Yizhuang,Beijing. CasGene Biotech is a privately-held Enterprise with locations in Yizhuang, Beijing, Changping, Beijing and Dallas. For more information, please visit www.casgene.com
About iPharm Pharm, Ltd.
iPhase Pharma Service (IPS) is a Contract Research Organization (CRO) founded by a group of professionals from US pharmaceutical and contract service industries. iPhase Pharma Services offers broad and integrated services for pharmaceutical and biotechnology companies. With our state-of-the-art instruments, AAALAC accredited GLP facility, Phase I clinical center, and professional team in nonclinical, clinical, and bioanalysis, we provide our partners optimal outsourcing solutions ranging from drug discovery, drug metabolism and pharmacokinetics, clinical bioavailability/bioequivalence, and bioanalytical services. For more information, please visit www.iphasepharma.com
